Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. OncologyPRO
  2. Meeting Resources
  3. ESMO Breast Cancer Congress 2023

Seagen - Case by case: How to optimize HER2+ metastatic breast cancer (MBC) treatment in second line and beyond

Progression after T-DXd: What to do in 3L? (case-based discussion)

Date

12 May 2023

Session

Seagen - Case by case: How to optimize HER2+ metastatic breast cancer (MBC) treatment in second line and beyond

Topics

Tumour Site

Breast Cancer

Presenters

Joyce O'Shaughnessy

Authors

J. O'Shaughnessy

Author affiliations

  • Texas Oncology, Dallas/US

Resources

This content is available to ESMO members and event participants.
Login

Resources from the same session

Welcome and introductions

Presenter: Andreas Schneeweiss

Session: Seagen - Case by case: How to optimize HER2+ metastatic breast cancer (MBC) treatment in second line and beyond

Resources:

Webcast

Evolving treatment landscape

Presenter: Andreas Schneeweiss

Session: Seagen - Case by case: How to optimize HER2+ metastatic breast cancer (MBC) treatment in second line and beyond

Resources:

Webcast

Q&A / Key takeaways

Presenter: To be Announced

Session: Seagen - Case by case: How to optimize HER2+ metastatic breast cancer (MBC) treatment in second line and beyond

Resources:

Webcast

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.